Alicia Secor, Atalanta Therapeutics CEO
Atalanta gets $97M boost to take two siRNAs into clinic for rare neuro disorders
For five years, Atalanta Therapeutics operated with one investor.
Now, F-Prime Capital is getting a bevy of financial support to propel two of the Boston …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.